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This short reviewwill summarize the current knowledge on the uptake, storage, and export
of copper ions by astrocytes and will address the potential roles of astrocytes in copper
homeostasis in the normal and diseased brain. Astrocytes in culture efficiently accumulate
copper by processes that include both the copper transporter Ctr1 and Ctr1-independent
mechanisms. Exposure of astrocytes to copper induces an increase in cellular glutathione
(GSH) content as well as synthesis of metallothioneins, suggesting that excess of
copper is stored as complex with GSH and in metallothioneins. Furthermore, exposure of
astrocytes to copper accelerates the release of GSH and glycolytically generated lactate.
Astrocytes are able to export copper and express the Menkes protein ATP7A. This protein
undergoes reversible, copper-dependent trafficking between the trans-Golgi network and
vesicular structures. The ability of astrocytes to efficiently take up, store and export copper
suggests that astrocytes play a key role in the supply of neurons with copper and that
astrocytes should be considered as target for therapeutic interventions that aim to correct
disturbances in brain copper homeostasis.
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INTRODUCTION
Astrocytes have many important functions in the brain, includ-
ing the maintenance of extracellular ion homeostasis, the mod-
ulation of synaptic transmission and plasticity, the supply of
metabolites, and the defense of the brain against oxidative stress
and toxins (Parpura et al., 2012; Schmidt and Dringen, 2012).
In addition, astrocytes are considered as key regulators of the
homeostasis of the redox-active metals iron and copper in the
brain (Dringen et al., 2007; Tiffany-Castiglioni et al., 2011;
Scheiber and Dringen, 2013). Copper is essential for brain cells
as a cofactor and structural component of various enzymes that
are involved in important biochemical pathways such as the res-
piratory chain, the antioxidative defense and the iron metabolism
(Scheiber and Dringen, 2013). However, excess of copper in
cells is harmful, since copper in redox-active form can catalyze
the production of hydroxyl radicals in a Fenton-like reaction,
thereby inducing oxidative stress and cell damage (Halliwell and
Gutteridge, 2007). Thus, a tight regulation of cellular copper
metabolism is required in order to ensure sufficient availability
of copper for essential enzymes without concomitant copper-
induced oxidative damage.
The presence of many copper-containing enzymes in astro-
cytes (Scheiber andDringen, 2013) demonstrates that brain astro-
cytes require copper as essential element. Histochemical staining
of brain sections revealed that copper is present in astrocytes in
normal brain (Szerdahelyi and Kasa, 1986). Elevated astrocytic
copper levels have been found in the brains of North Ronaldsay
sheep, an animal model for copper toxicosis (Haywood et al.,
2008). Astrocytes have been reported to be remarkably resistant
against copper-induced toxicity (Chen et al., 2008; Reddy et al.,
2008; Scheiber and Dringen, 2013). Thus, these cells appear to
be equipped with the machinery to deal well with even large
amounts of copper. This short review will summarize the current
knowledge on the uptake, storage and export of copper in cul-
tured astrocytes and will describe alterations of basal metabolic
pathways of astrocytes after exposure to copper. Finally, we will
address the potential roles that astrocytes may play in the cop-
per homeostasis of the normal brain and in the dysregulation of
copper homeostasis that has been connected with a number of
human diseases.
UPTAKE STORAGE AND EXPORT OF COPPER
COPPER UPTAKE
Several groups have reported that cultured astrocytes efficiently
accumulate copper (Brown, 2004; Scheiber et al., 2010a,b, 2012;
Qian et al., 2012). The apparent KM value for copper uptake
of about 10μM as well as the expression of the copper trans-
porter receptor 1 (Ctr1) in cultured astrocytes (Scheiber et al.,
2010a) suggest that this transporter is responsible for the high
affinity copper uptake into astrocytes (Figure 1). However, the
inhibition of copper accumulation in astrocytes by zinc (Scheiber
et al., 2010a,b) suggests that Ctr1-independent transport pro-
cesses also contribute to the astrocytic copper accumulation.
Transporters that could mediate Ctr1-independent copper uptake
into astrocytes include the divalent metal transporter 1 (DMT1)
and members of the Zrt/IRT-like protein (ZIP) family (Scheiber
et al., 2010a; Scheiber and Dringen, 2013). Since Cu+ has been
reported to be the copper species transported by both Ctr1
and DMT1 (Lee et al., 2002; Arredondo et al., 2003), an ecto-
cuprireductase on the plasma membrane of astrocytes and/or
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FIGURE 1 | Copper metabolism of astrocytes. Copper is taken up into
astrocytes by the copper transporter receptor 1 (Ctr1) and also by
Ctr1-independent mechanisms which may include the divalent metal
transporter 1 (DMT1) or members of the ZIP family of metal
transporters. An ecto-cuprireductase and/or extracellular ascorbate will
provide the reduced copper species for astrocytic uptake by Ctr1 or
DMT1. Accumulated copper is stored in astrocytes as complex with
GSH or in metallothioneins (MT). In addition, copper is shuttled to its
specific cellular target, by the copper chaperones CCS to superoxide
dismutase 1 (SOD1), by Cox17 to Sco1/2 and Cox11 for subsequent
incorporation into cytochrome c oxidase and by antioxidant protein
1 (Atox1) to ATP7A. ATP7A transports copper into the trans-Golgi
network for subsequent incorporation into copper-dependent enzymes.
When the cellular copper level rises above a certain threshold, ATP7A
translocates reversibly via vesicles to the plasma membrane to export
copper.
astrocyte-derived ascorbate (Scheiber and Dringen, 2013) may
be involved in reducing extracellular Cu2+ to the Cu+ that
is subsequently taken up into astrocytes (Figure 1). An addi-
tional protein that has been suggested to contribute to the
astrocytic copper uptake or export is the prion protein (Brown,
2004).
STORAGE AND INTRACELLULAR TRAFFICKING OF COPPER
Despite of their efficient accumulation of exogenous copper,
astrocytes have been reported to be remarkably resistant to
copper-induced toxicity (Chen et al., 2008; Reddy et al., 2008;
Scheiber and Dringen, 2013). The most likely reason for this resis-
tance is that astrocytes have a high capacity to store excess copper
as complex with glutathione (GSH) and inmetallothioneins (MT;
Figures 1, 2) which keep the excess copper bound in a non-toxic
form. When exposed to copper cultured astrocytes elevate their
cellular levels of GSH (Scheiber and Dringen, 2011a) and MT
(Scheiber and Dringen, 2013), thereby increasing their storage
capacity for copper.
For incorporation into copper-dependent enzymes, copper
is shuttled to its target proteins by specific copper chap-
erones (Robinson and Winge, 2010). The copper chaperone
for Cu/Zn superoxide dismutase (CCS) that delivers cop-
per to Cu/Zn superoxide dismutase is expressed in astro-
cytes (Rothstein et al., 1999). In contrast, expression of
Atox1 and Cox17, which deliver copper to ATP7A and to
cytochrome c oxidase, respectively, has not been reported so far
for astrocytes. However, as astrocytes express functional ATP7A
(Scheiber et al., 2012) and cytochrome c oxidase (Bolaños and
Heales, 2010), Atox1 and Cox17 are likely to be expressed in
these cells.
EXPORT OF COPPER
Cellular export of copper is mediated by the copper ATPases
ATP7A and ATP7B which are mutated in the human disor-
ders Menkes disease and Wilson’s disease, respectively (Huster,
2010; Kaler, 2011). Cultured astrocytes have recently been shown
to export copper in a time-, concentration- and temperature-
dependent manner (Scheiber et al., 2012). This copper export
is most likely mediated by ATP7A (Figure 1) as this protein is
expressed in astrocytes in culture and in brain (Barnes et al., 2005;
Niciu et al., 2007; Scheiber et al., 2012). The copper-dependent
trafficking of ATP7A between the trans-Golgi network and sites
close to the plasma membrane (Scheiber et al., 2012) strongly
suggests a contribution of ATP7A in copper export from astro-
cytes. This view is also supported by the marked accumulation
of copper in astrocytes derived from the macular mouse model
of Menkes disease (Kodama et al., 1991). The potential of astro-
cytes to export copper suggests that these cells can supply other
types of brain cells with copper and that impaired copper supply
from astrocytes contributes to the neuronal copper deficiency in
Menkes disease (Figure 2).
Frontiers in Aging Neuroscience www.frontiersin.org March 2013 | Volume 5 | Article 9 | 2
Dringen et al. Copper and astrocytes
FIGURE 2 | Proposed model of astrocytic copper supply to neurons.
(A) In the normal brain, copper is efficiently taken up by astrocytes via Ctr1
and other transporters which are so far not identified. Excess of copper is
stored by astrocytes in MT or as GSH complex and copper is released via
ATP7A to supply neurons with copper. (B) In copper overload conditions,
excess of copper is efficiently taken up into astrocytes and stored in MT or
as GSH complex to prevent copper-induced neurotoxicity. (C) In Menkes
disease, astrocytes accumulate and store copper, but the mutated ATP7A is
unable to mediate astrocytic copper export and copper supply to neurons.
MODULATION OF ASTROCYTIC METABOLISM BY COPPER
Elevation of the cellular copper content of cultured astrocytes
caused a time- and concentration-dependent acceleration in
glucose consumption and lactate release (Scheiber and Dringen,
2011b). This consequence of copper treatment appears not
to be mediated by mitochondrial impairment, but was pre-
vented by inhibition of protein synthesis (Scheiber and Dringen,
2011b). Thus, the copper-induced stimulation of glycolytic
flux in astrocytes is likely to depend on transcription and/or
translation. Copper-activated transcription factors such as the
nuclear factor kappa B or the metal transcription factor 1 have
been suggested to contribute to the copper-induced stimula-
tion of glycolytic flux in astrocytes (Scheiber and Dringen,
2013).
Elevated copper content also affects the GSH metabolism
of astrocytes. Exposure to copper chloride markedly increased
the cellular GSH content of cultured astrocytes (Scheiber and
Dringen, 2011a). Copper-induced increase in γ-glutamate cys-
teine ligase activity by a post-translational mechanism and
increased uptake of the GSH precursors cysteine or cysteine
into astrocytes have been suggested as potential reasons for
the increased specific GSH content of copper-treated astrocytes
(Scheiber and Dringen, 2011a, 2013). A compromised GSH
export which has been reported to increase cellular GSH contents
in astrocytes (Minich et al., 2006) can be excluded as a contributor
to the increased cellular GSH content of copper-treated astro-
cytes, as the GSH export is accelerated in copper-loaded astrocytes
(Scheiber and Dringen, 2011a). This accelerated, temperature-
sensitive GSH export is mediated by the multidrug resistance
protein 1 and is considered to be a direct consequence of the
increased cellular GSH concentration in copper-treated astrocytes
(Scheiber and Dringen, 2011a).
FUNCTIONS OF ASTROCYTES IN THE COPPER METABOLISM
OF NORMAL AND DISEASED BRAIN
The ability of astrocytes to efficiently take up, store and export
copper suggests that these cells serve as key regulators of the
copper homeostasis in the brain (Tiffany-Castiglioni et al., 2011;
Scheiber and Dringen, 2013). Efficient copper uptake and stor-
age in astrocytes serves to protect other brain cells against copper
toxicity. The known high antioxidative potential of astrocytes
(Dringen et al., 2005) is likely to protect these cells from acute
copper toxicity, while the upregulation of the cellular copper
storage capacity by induction of MT synthesis (Scheiber and
Dringen, 2013) and by elevated GSH synthesis (Scheiber and
Dringen, 2011a) will contribute to the prolonged resistance of
astrocytes against copper-induced toxicity. In addition, the abil-
ity of astrocytes to export copper suggests that astrocytes are able
to provide copper to neurons and other neighboring cells in the
brain (Figure 2). Further studies are required to investigate how
signals derived from neurons and/or other types of brain cells will
affect the basal coppermetabolism of astrocytes and whether such
signals could modulate the copper export from astrocytes.
Disturbances in copper homeostasis in brain occur in both
Menkes disease and Wilson’s disease (Kaler, 2011; Kodama
et al., 2011), but also in other neurodegenerative disorders such
as Alzheimer’s disease and Parkinson’s disease (Rivera-Mancia
et al., 2010; Double, 2012; Greenough et al., 2013; Scheiber and
Dringen, 2013). The role of astrocytes in the copper homeosta-
sis of the brain in these disorders should be considered. The
impaired supply of copper from astrocytes to neurons due to
mutations of the Menkes protein ATP7A may foster the neu-
ronal copper deficiency in Menkes disease, while the capacity of
astrocytes to uptake and store excess of copper may be insuf-
ficient to protect neurons against the excess of copper present
in the brain in Wilson’s disease (Figure 2). In addition, the dis-
turbances in the distribution of brain copper in Alzheimer’s
disease (Greenough et al., 2013) may reflect impaired supply
of copper from astrocytes to neurons (Scheiber and Dringen,
2013). The ability of astrocytes to efficiently accumulate, store
and export copper makes this brain cell type to an interest-
ing target for therapeutic strategies that aim to correct the
observed disturbances in copper metabolism in human disorders
(Greenough et al., 2013; Liddell et al., 2013).
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